Know Cancer

forgot password

Open (Enrolling)
Gastric Intestinal Metaplasia

Thank you

Trial Information

Study population and Sample size at Faculty of Medicine, Chulalongkorn University The
patients who were diagnosed gastric intestinal metaplasia from 1997 to 2012 and then follow
up for 5 years. Estimate sample size =280

- Investigational product, dosage & route of administration

- Questionnaire for explore the risk factors

- EGD with biopsy

- Blood sampling for gastro panel

- Duration of participation

- 5 years or until diagnose gastric cancer

Statistical method:

Unconditional-binary-logistic regression

Inclusion Criteria:

1. All patients were diagnosed GIM

2. All patients have to sign the consent form

Exclusion Criteria:

1. Previous gastric surgery including gastrectomy and bypass surgery

2. Bleeding tendency including decompensated cirrhosis, chronic kidney disease and
long-tem antiplatelets or anticoagulants

3. HIV infection

4. History of proton pump inhibitor use within 1 week

5. History of antibiotic use within 4 weeks

Type of Study:


Study Design:

Time Perspective: Prospective

Outcome Measure:

The prevalence of early gastric cancer in gastric intestinal metaplasia(GIM) patient from 5 year-follow-up in Thai population

Outcome Description:

In Thailand, gastric cancer patients usually presented with advance stage and carried the dismal prognosis. GIM is a well known precancerous lesion. The appropriate follow-up period in high risk GIM patient can increase the prevalence of early gastric cancer and reduce the mortality rate of gastric cancer

Outcome Time Frame:

Up to 5 years

Safety Issue:


Principal Investigator

Rungsun Rerknimitr, Professor

Investigator Role:

Study Director

Investigator Affiliation:

King Chulalongkorn Memorial Hospital


Thailand: Ethical Committee

Study ID:




Start Date:

October 2011

Completion Date:

October 2017

Related Keywords:

  • Gastric Intestinal Metaplasia
  • Gastric intestinal metaplasia
  • Metaplasia
  • Gastritis, Atrophic